We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

27 hedge funds and large institutions have $3.4M invested in Oramed Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

25% more capital invested

Capital invested by funds: $2.73M → $3.4M (+$678K)

23% more funds holding

Funds holding: 22 → 27 (+5)

0.58% more ownership

Funds ownership: 2.06% → 2.64% (+0.58%)

68% less call options, than puts

Call options by funds: $9K | Put options by funds: $28K

Holders
27
Holders Change
+5
Holders Change %
+22.73%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
3
Closed
1
Calls
$9K
Puts
$28K
Net Calls
-$19K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$203K
2
Millennium Management
Millennium Management
New York
+$152K
3
UBS Group
UBS Group
Switzerland
+$143K
4
OAM
Oxford Asset Management
United Kingdom
+$120K
5
Renaissance Technologies
Renaissance Technologies
New York
+$100K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$40.9K
2
PMFA
Plante Moran Financial Advisors
Michigan
-$3K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.75K
4
TRCT
Tower Research Capital (TRC)
New York
-$2.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$842K +$100K +10,500 +13%
Barclays
2
Barclays
United Kingdom
$371K – – –
Morgan Stanley
3
Morgan Stanley
New York
$324K +$203K +21,228 +144%
Deutsche Bank
4
Deutsche Bank
Germany
$311K +$49.5K +5,174 +18%
PNC Financial Services Group
5
PNC Financial Services Group
Pennsylvania
$191K – – –
GT
6
Glenmede Trust
Pennsylvania
$180K – – –
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$166K -$2.75K -288 -2%
UBS Group
8
UBS Group
Switzerland
$157K +$143K +14,945 +602%
Millennium Management
9
Millennium Management
New York
$143K +$152K +15,849 New
RPC
10
Rossmore Private Capital
Connecticut
$136K +$144K +15,061 New
OAM
11
Oxford Asset Management
United Kingdom
$116K +$120K +12,575 New
Group One Trading
12
Group One Trading
Illinois
$103K +$37K +3,872 +51%
EMG
13
ETF Managers Group
New Jersey
$102K +$17.1K +1,792 +19%
Wells Fargo
14
Wells Fargo
California
$94K -$40.9K -4,275 -29%
Macquarie Group
15
Macquarie Group
Australia
$32K +$33.5K +3,499 New
SIAP
16
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$28K – – –
FANJ
17
Financial Architects (New Jersey)
New Jersey
$25K – – –
Bank of Montreal
18
Bank of Montreal
Ontario, Canada
$23K +$9.56K +1,000 +63%
JP Morgan Chase
19
JP Morgan Chase
New York
$15K +$7.79K +815 +92%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$14K +$9.56K +1,000 +200%
Bank of America
21
Bank of America
North Carolina
$10K – – –
CAM
22
Close Asset Management
United Kingdom
$7K – – –
JWA
23
JFS Wealth Advisors
Pennsylvania
$5K – – –
CA
24
Calton & Associates
Florida
$3K +$4.3K +450 New
LC
25
Landaas & Company
Wisconsin
$2K – – –
1
2

ORMP Hedge Fund Activity: Q4 2017 in Review

27 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2017, worth a combined $3.4M — up 25% from $2.73M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ORMP positions and 1 closed out — a net gain of 5 holders — while 9 added to existing stakes and 3 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $203K. The largest seller was Wells Fargo, cutting an estimated $40.9K.

  • 27 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2017, up from 22 in Q3 2017.
  • Funds reported $3.4M of Oramed Pharmaceuticals stock for Q4 2017, up 25% quarter-over-quarter.
  • 6 funds opened new Oramed Pharmaceuticals positions in Q4 2017 and 1 closed out, a net change of +5 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2017 was Morgan Stanley, an estimated $203K added.
  • The largest Oramed Pharmaceuticals seller in Q4 2017 was Wells Fargo, an estimated $40.9K sold.

Based on aggregated 13F filings for Q4 2017.